Sandwich Assay Patents (Class 435/7.94)
-
Publication number: 20130171673Abstract: The present invention relates to a pipette tip (100, 200, 201, 300) comprising a tip body (110) having an inner surface and an outer surface (112). The inner surface (111) defines an inner cavity (120, 320), which has an upper end and a lower end. The upper end has an upper opening (131); and the lower end has a lower opening (141). At least a part of the inner surface (111) is provided with capturing agents (151) of at least one type forming at least one capturing-agent region (150) on the at least one inner surface. The at least one capturing agent region (150) is capable of selectively binding target substances (152) of at least one type comprised in a sample to form at least agent-target conjugates (155), the arrangement of which define at least one agent-target region (156).Type: ApplicationFiled: June 30, 2011Publication date: July 4, 2013Applicant: CSEM CENTRE SUISSE D'ELECTRONIQUE ET DE MICRO- TECHNIQUE SA RECHERCHE ET DEVELOInventors: Stéphane Follonier, Linsey Fan, Pierre Indermuhle
-
Publication number: 20130171672Abstract: Methods and products for the detection of oncofetal fibronectin indicating molecules in samples are provided. Methods for imaging of oncofetal fibronectin are provided. In some methods provided herein, the sample is treated with a reagent and/or contacted with a non-specific binder. Provided are methods for testing subjects to ascertain health and disease status and to assess the risk of developing a disease or condition. Methods for detecting the presence of oncofetal fibronectin indicating molecules by a variety of methods such as immunoassays and mass spectrometry also are provided.Type: ApplicationFiled: February 11, 2013Publication date: July 4, 2013Applicant: HOLOGIC, INC.Inventor: Hologic, Inc.
-
Patent number: 8476033Abstract: Compositions and methods for diagnosing ovarian cancer in a patient and for identifying patients with an increased likelihood of having ovarian cancer are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to glycodelin. Monoclonal antibodies having the binding characteristics of a glycodelin antibody of the invention and monoclonal antibodies that bind to a glycodelin epitope of a disclosed antibody are further provided. Hybridoma cell lines that produce a glycodelin monoclonal antibody of the invention are also disclosed herein. Kits comprising one or more of the disclosed glycodelin monoclonal antibodies and for practicing the methods of the invention are further provided. Polypeptides comprising the amino acid sequence for a glycodelin epitope of a disclosed monoclonal glycodelin antibody and methods of using these polypeptides in the production of glycodelin antibodies are also encompassed by the present invention.Type: GrantFiled: July 27, 2012Date of Patent: July 2, 2013Assignee: TriPath Imaging, Inc.Inventors: Robert L. Cheek, Eric P. Dixon, Timothy J. Fischer, John W. Groelke, Steven L. Knapp, Stephen G. Simkins, Clark M. Whitehead
-
Patent number: 8476027Abstract: A binding partner, especially an antibody fragment that specifically recognizes an antigen-antibody immune complex between anti-THC and THC (tetrahydrocannabinol), is disclosed. The binding partner facilitates a non-competitive homogenous immunoassay for detection of cannabis use. A test kit comprising the binding partner is also described. Preferably the immunoassay is applied for roadside testing of saliva from suspected drivers.Type: GrantFiled: June 5, 2009Date of Patent: July 2, 2013Assignee: Teknologian Tutkimuskeskus VTTInventors: Kristiina Takkinen, Hans Söderlund, Timo Pulli
-
Publication number: 20130165345Abstract: The present invention relates to a reliable method of prediction of infectious peritonitis in humans, wherein the level of pancreatic stone protein/regenerating protein (PSP/reg) is determined in serum or plasma, and a high level is indicative of the development and the severity of peritonitis, allowing the classification of patients according to risk.Type: ApplicationFiled: August 30, 2011Publication date: June 27, 2013Applicant: Universitaet ZuerichInventors: Walter Halangk, Rolf Graf, Raphael Gukasjan, Hans-Ulrich Schulz
-
Publication number: 20130156783Abstract: The present invention is directed to pharmaceutical agents and compositions useful for the treatment and prevention of amyloid disease in a subject. The invention further relates to isolated antibodies that recognize a common conformational epitope of amyloidogenic proteins or peptides that are useful for the diagnosis, treatment, and prevention of amyloid disease.Type: ApplicationFiled: February 21, 2013Publication date: June 20, 2013Applicant: NEW YORK UNIVERSITYInventor: NEW YORK UNIVERSITY
-
Publication number: 20130157296Abstract: Provided is a recombination protein which binds specifically to troponin I derived from human myocardium. The recombinant protein includes a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 63; and a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 65.Type: ApplicationFiled: December 27, 2012Publication date: June 20, 2013Applicant: PANASONIC CORPORATIONInventor: PANASONIC CORPORATION
-
Publication number: 20130157297Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Alpha-2-HS-glycoprotein, Interleukin-9, Leukemia inhibitory factor, Macrophage colony-stimulating factor 1, Prolactin, and Stromal cell-derived factor 12 as diagnostic and prognostic biomarkers in renal injuries.Type: ApplicationFiled: June 23, 2011Publication date: June 20, 2013Applicant: ASTUTE MEDICAL, INC.Inventors: Joseph Anderberg, Jeff Gray, Paul McPherson, Kevin Nakamura, James Patrick Kampf
-
Publication number: 20130149316Abstract: The present inventors successfully produced monoclonal antibodies that are specific to only soluble A? oligomers, but do not recognize soluble A? monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease.Type: ApplicationFiled: February 6, 2013Publication date: June 13, 2013Applicants: National Center for Geriatrics and Gerontology, Immunas Pharma, Inc.Inventors: Immunas Pharma, Inc., National Center for Geriatrics and Gerontology
-
Publication number: 20130149726Abstract: The invention relates to certain methods for the determination of an antigen content of a first antigen in a mixture comprising two or more antigens. The invention also relates to a potency test for an antigen in a combination vaccine. The method allows the determination of the antigen content in a mixture additionally comprising antibodies that are capable of binding with the antigen.Type: ApplicationFiled: February 5, 2013Publication date: June 13, 2013Inventors: MICHELLE ALLEN, MARK GARRETT, URS PETER BRUDERER, MARTINUS ANTONIUS JOHANNES THIJSSEN
-
Patent number: 8460891Abstract: Described herein are monoclonal antibodies and methods useful for determining and quantitating the presence of an aryloxyalkanoate dioxygenase enzyme.Type: GrantFiled: June 2, 2011Date of Patent: June 11, 2013Assignee: Dow Agrosciences LLC.Inventors: Guomin Shan, Gaofeng Lin, Joelene K. Smith Drake, Marcelo Sosa
-
Patent number: 8460618Abstract: The invention is directed to an apparatus useful in conducting detection of compounds on blotting membranes. The device is comprised of several layers including a porous support layer below the blotting membrane(s), a flow distributor above the blotting membrane(s) and optionally a well on the flow distributor to contain the liquid to the desired area and to allow for lower starting volumes of such liquid. Preferably, the flow distributor is a non-binding or low binding hydrophilic porous membrane such as a 0.22 micron membrane and the support layer is a grid or sintered porous material. The distributor and support are held together to form an envelope around the membrane(s). The use of a hinge, clips and other such devices is preferred in doing so.Type: GrantFiled: October 25, 2010Date of Patent: June 11, 2013Assignee: EMD Millipore CorporationInventors: Masaharu Mabuchi, Hiroko Ykohama, Marc Emerick, Phillip Clark, Kurt Greenizen
-
Publication number: 20130143245Abstract: Provided is a recombination protein which binds specifically to troponin I derived from human myocardium. The recombinant protein includes a light chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 63; and a heavy chain variable region consisting of the amino acid sequence represented by SEQ ID NO: 65.Type: ApplicationFiled: September 26, 2012Publication date: June 6, 2013Applicant: PANASONIC CORPORATIONInventor: Panasonic Corporation
-
Patent number: 8455212Abstract: The present disclosure relates to assays for detecting and/or quantifying the amount of human NT-pro B-type natriuretic peptide, human pro B-type natriuretic peptide and human B-type natriuretic peptide in a test sample.Type: GrantFiled: November 21, 2009Date of Patent: June 4, 2013Assignee: Abbott LaboratoriesInventors: John George Konrath, Jeffrey Allen Moore
-
Patent number: 8456158Abstract: A magnetic binding substance, which is a first binding substance that specifically binds with a target substance, having magnet enveloping dielectric particles, which have magnetic particles enveloped therein and surfaces modified with functional groups that exhibit polarity within a liquid sample, attached thereto, and a labeling binding substance, which is a second binding substance that specifically binds with the target substance having photoresponsive labels attached thereto, are mixed with the liquid sample such that binding reactions occur. A magnetic field is generated within a sample cell, to draw the magnetic binding substance to a local region. Excitation light is irradiated only onto a predetermined region including the local region while the magnetic binding substance is drawn to the local region, causing the photoresponsive labels present therein to generate optical signals. The optical signals are detected.Type: GrantFiled: July 28, 2010Date of Patent: June 4, 2013Assignee: FUJIFILM CorporationInventor: Hisashi Ohtsuka
-
Publication number: 20130137124Abstract: Methods for determining the risk of developing acute renal failure in a human subject by measuring human neutrophil gelatinase-associate lipocalin (NGAL) are provided.Type: ApplicationFiled: January 18, 2013Publication date: May 30, 2013Applicant: AntibodyShop A/SInventor: AntibodyShop A/S
-
Publication number: 20130137592Abstract: An object of the present invention is to provide biomarkers for predicting response to chemoradiotherapy for cancer and predicting prognosis of a patient with cancer, as well as methods of measuring such biomarkers. The response to chemoradiotherapy for cancer in a vertebrate animal can be predicted by measuring concentrations of a soluble interleukin-6 receptor, MIP-1?, and an activated plasminogen activator inhibitor in the blood obtained from that individual with cancer before treatment with chemoradiotherapy, and prognosis of the same vertebrate animal can be determined by measuring a concentration of soluble interleukin-6 receptor.Type: ApplicationFiled: March 31, 2011Publication date: May 30, 2013Applicant: NATIONAL CANCER CENTERInventors: Kazufumi Honda, Tesshi Yamada, Yosuke Makuuchi, Yoshiaki Osaka, Setsuo Hirohashi
-
Patent number: 8450068Abstract: The present invention provides an assay for detecting serum IgE antibody levels to cetuximab and to other proteins. The present invention further provides a method for predicting whether a subject will respond adversely to cetuximab treatment. The present further provides a method for detecting sensitivity to compounds comprising galactose-alpha-1,3-galactose.Type: GrantFiled: February 15, 2008Date of Patent: May 28, 2013Assignee: University of Virginia Patent FoundationInventors: Thomas A. E. Platts-Mills, Tina Hatley Merritt
-
Publication number: 20130130288Abstract: This invention is a selective A? oligomer kit and immunoassay method capable of reliably and sensitively detecting A? oligomers in a biological sample of a patient. In one embodiment the inventive assay uses a pair of anti-A? oligomer antibodies, as capture and detection antibodies, to detect and quantify A? oligomers. The method can be used to differentiate Alzheimer's disease (AD) patients from non-AD patients and/or to stratify AD patients according to the severity of their disease.Type: ApplicationFiled: July 9, 2012Publication date: May 23, 2013Inventor: William F. Goure
-
Publication number: 20130130233Abstract: The present invention relates to novel monoclonal antibodies which may be used in the detection of Human Immunodeficiency Virus (HIV). These antibodies exhibit an unusually high degree of sensitivity, a remarkably broad range of specificity, and bind to novel shared, non-cross-reactive epitopes. In particular, the monoclonal antibodies of the present invention may be utilized to detect HIV-1 antigen and HIV-2 core antigen in a patient sample.Type: ApplicationFiled: October 9, 2012Publication date: May 23, 2013Applicant: ABBOTT LABORATORIESInventor: Abbott Laboratories
-
Patent number: 8445220Abstract: Disclosed are procedures and methods for diagnosing latent and active cancers in a subject. The described methods include the use of sandwich ELISA assays containing antibodies specific for certain epitopes on the A-protein. This enables the assay to discriminate between the monomelic and homopolymeric forms of A-protein.Type: GrantFiled: November 8, 2012Date of Patent: May 21, 2013Assignee: ASK Diagnostics, Inc.Inventor: Geoffrey Schmidt
-
Publication number: 20130123281Abstract: Compositions and methods which modulate diseases and disorders related to transducin ?-like protein 1 (TBL1) activity, including but not limited to cancer, inflammation, and bone related diseases.Type: ApplicationFiled: November 12, 2012Publication date: May 16, 2013Applicant: BETA CAT PHARMACEUTICALS, LLCInventors: Hariprasad M. Vankayalapati, Stephen Horrigan
-
Publication number: 20130122530Abstract: Systems, kits, and methods for predicting the risk of an adverse event related to acute kidney injury AKI as a consequence of a surgical intervention in a subject. Embodiments of the system and methods include means and steps for determining an amount of liver-type fatty acid binding protein (L-FABP) in a sample, such as a urine-sample of a subject; comparing the amounts of the L-FABP with a reference amount, and predicting the risk of an adverse event related to acute kidney injury as a consequence of surgical intervention in the subject.Type: ApplicationFiled: December 13, 2012Publication date: May 16, 2013Applicant: ROCHE DIAGNOSTICS OPERATIONS, INC.Inventor: Roche Diagnostics Operations, Inc.
-
Publication number: 20130123121Abstract: The present disclosure is directed to methods and/or uses of oligonucleotide-bead conjugates for assays and detections and related systems and/or kits. Certain methods are directed to a method for detecting one or more biological targets of a sample in a detection assay, comprising: providing a molecular probe, comprising a binding moiety and an oligonucleotide sequence, to a sample comprising one or more biological targets; binding the one or more biological targets with the binding moiety; providing a detectable component to the sample, wherein the detectable component comprises a signal generating moiety conjugated to an oligonucleotide sequence complementary to the oligonucleotide sequence of the molecular probe; hydridizing the oligonucleotide sequence of the target-bound molecular probe to the detectable component; and detecting a signal generated from the hydridized detectable component. Various other embodiments, applications etc. are disclosed herein.Type: ApplicationFiled: November 22, 2011Publication date: May 16, 2013Applicants: The University of Chicago, SoluLink, Inc.Inventors: David A. Schwartz, Jimmy Williams, Xinfang Zhao, Chunfang Zhao, William B. Busa, Stephen J. Kron, Amy Catherine Flor
-
Publication number: 20130122529Abstract: A method for diagnosing or predicting the risk of developing preeclampsia by measuring the level of A1 M and one or more of the compounds HbA, HbF in a sample and comparing the obtained values with reference values. By using a combination of information relating to A1 M and HbF improved diagnose or prediction is observed.Type: ApplicationFiled: March 24, 2011Publication date: May 16, 2013Applicant: Preelumina Diagnostics ABInventors: Bo Akerstrom, Magnus Gram, Stefan Hansson
-
Publication number: 20130123145Abstract: Multiplexed assays are disclosed for detection of duster differentiation 4 (CD4) glycoprotein expressed on the cell surface of I-helper cells, monocytes, macrophages, and dendritic cells; cluster differentiation 25 (CD25), a type transmembrane protein present on activated T-cells, activated B-cells, thymocytes, myeloid precursors, and oligodendrocytes; and Forkhead box P3 (FOXP3), an intracellular protein involved in immune system responses in cell cultures, tissues samples, humans, and biological samples. The multiplexed assays can be used to detect 1r-cells, activated I-cells, and other similar cell types (e.g. natural T regulatory cells, adaptive/induced T regulatory T cells). The multiplexed assays employ quantum dots of various shapes, types, compositions, coatings, sizes, ligands and other such characteristics.Type: ApplicationFiled: December 22, 2012Publication date: May 16, 2013Applicant: NNANOAXIS, LLCInventors: Krishnan Chakravarthy, Siddhartha Kamisetti
-
Publication number: 20130122519Abstract: The present invention relates to the identification and use of diagnostic markers for ischemic stroke of the lacunar subtype. The invention relates to devices and kits for performing these methods.Type: ApplicationFiled: July 28, 2011Publication date: May 16, 2013Applicants: Institut de recerca Hoepital Universitari Vall D'Heerbron, Fundacio Privada, ABBOTT GMBH & CO. KGInventors: Ingo Curdt, Stuart Blincko, Jens Dhein, Viswanath Devanarayan, Joan Montaner Villalonga
-
Publication number: 20130115639Abstract: The invention relates to a diagnostic method to detect a salmonellae infection and/or salmonellae contamination. Fields of use include medicine, veterinary medicine and various branches of industry. The goal of the invention is to develop a reliable test to identify salmonellae. It is based on the task of designing a method that allows the earliest possible identification and covers all important serovars. The diagnostic method to detect a salmonellae infection/contamination in accordance with the invention is characterised in that the SipC of all known salmonellae serovars excreted by the salmonellae can be identified in excretions of patients/animals, carcasses, eggs and food/animal feed.Type: ApplicationFiled: April 14, 2011Publication date: May 9, 2013Applicant: BIOSERV ANALYTIK UND MEDIZINPRODUKTE GMBHInventors: Udo Meyer, Alain Steinmann, Heike Fahlandt, Babette Schulz
-
Publication number: 20130115640Abstract: Provided herein are methods for prophylactic treatment of Diabetes Mellitus comprising administration of adrenocorticotropic hormone (ACTH), or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual suspected of having, predisposed to, or at risk of developing Diabetes Mellitus. Also provided herein are methods for monitoring treatment of Diabetes Mellitus by measuring and monitoring levels of MCP-1, TGF-?, VEGF A and VEGF B.Type: ApplicationFiled: November 2, 2012Publication date: May 9, 2013Inventors: James A. Tumlin, Claude Galphin, Brad Rovin
-
Publication number: 20130115638Abstract: The present invention concerns a procedure and a device to determine the concentration of protamine-1 and protamine-2 and the ratio between protamine-1 and protamine-2 as protamine/protein ratio in a questionable sample from an individual to be examined in order to assess the fertility of the sperm in vitro. This assessment is of great importance for the prognosis of the success of an artificial insemination of an egg in vitro. The test strip comprises a sperm pretest to determine the sperm concentration and a protamine rapid test to determine the concentrations of protamine-1 and protamine-2 and the ratio between protamine-1 and protamine-2 as protamine/protein ratio.Type: ApplicationFiled: May 17, 2011Publication date: May 9, 2013Applicant: JUSTUS-LIEBIG-UNIVERSITAET GIESSENInventors: Klaus Steger, Agnieszka Paradowska, Birte Bärmann
-
Publication number: 20130115612Abstract: The object of the present invention is to provide a clinical marker capable of distinguishing breast cancer from interstitial pneumonia; and a clinical marker for detecting malignancy or progress level of breast cancer, and for monitoring effects of the treatment of breast cancer. The object can be solved by a method for analyzing mucin 1 having Sia?2-8Sia?2-3Gal?-R, characterized by comprising the step of bringing a first probe specifically binding to a mucin 1 having Sia?2-8Sia?2-3Gal?-R into contact with a sample to be tested.Type: ApplicationFiled: May 6, 2011Publication date: May 9, 2013Applicants: YAMAGUCHI UNIVERSITY, TOKYO INSTITUTE OF TECHNOLOGYInventors: Katsuko Yamashita, Keiko Fukushima, Yuji Hinoda
-
Patent number: 8435755Abstract: The present invention relates to a reliable method of prediction of sepsis in humans after a trauma, wherein the level of pancreatic stone protein/regenerating protein (PSP/reg) is determined in serum, and a high level is indicative of the development of sepsis at early stages of the disease. Furthermore a method of determination of PSP/reg levels in serum is described.Type: GrantFiled: September 2, 2008Date of Patent: May 7, 2013Assignee: Universitaet ZuerichInventors: Rolf Graf, Daniel Bimmler, Marius Keel
-
POSITIVELY CHARGED SPECIES AS BINDING REAGENTS IN THE SEPARATION OF PROTEIN AGGREGATES FROM MONOMERS
Publication number: 20130109581Abstract: The invention provides methods for detecting the presence of an aggregate in a sample by contacting the sample suspected of containing an aggregate with an aggregate-specific binding reagent under conditions that allow the binding of the reagent to the aggregate, if present; and detecting the presence of the aggregate, if any, in the sample by its binding to the reagent; where the aggregate-specific binding reagent typically has a net charge of at least about positive one at the pH at which the sample is contacted with the ASB reagent, is attached to a solid support at a charge density of at least about 60 nmol net charge per square meter, and binds preferentially with aggregates over monomers when attached to the solid support. Methods for detecting the presence of oligomer are also provided. Compositions for use in the methods are provided.Type: ApplicationFiled: November 4, 2010Publication date: May 2, 2013Inventors: David Peretz, Alice Yam, Xuemei Wang, Man Gao -
Publication number: 20130108660Abstract: The present invention relates to the identification of nucleotide and peptide sequences of a novel HDL transporter located in the flagellar pocket of African trypanosome parasites, and to the use thereof for anti-trypanosomosis diagnostic, therapeutic and vaccine applications in man and in animals.Type: ApplicationFiled: November 10, 2010Publication date: May 2, 2013Inventors: Virginie Coustou Linares, Theo Baltz, Magali Thonnus
-
Patent number: 8431355Abstract: The present invention relates to the use of the assessment of the binding between—antibodies elicited against a first glycoprotein, and—at least one glycoform of a second glycoprotein, said second glycoprotein being itself a glycoform of the first protein, wherein said glycoform of the second glycoprotein is selected from a group of glycoforms of the second glycoprotein, each glycoform of said group corresponding to a determined glycosylation state defined by a determined sialylation state, and/or a determined branching state, and/or a determined fucosylation state, provided that said glycosylation state is not uniquely defined by a substantially unsialylated state, for the screening of glycoform specific antibodies directed against a given glycoform of the second glycoprotein.Type: GrantFiled: February 4, 2005Date of Patent: April 30, 2013Assignee: Universite de Provence Aix-Marseille 1Inventors: Catherine Ronin, Sandrine Donadio
-
Publication number: 20130101999Abstract: Multi-leg luminescent nanoparticles (“MLN's”) that can be paired to other MLN's as well s biological molecules to film branched multi-leg luminescent nanoparticles (“BMLN's) that can be used in biological multiplexing applications, imaging applications, biological detection applications and other biological applications.Type: ApplicationFiled: September 25, 2012Publication date: April 25, 2013Applicant: NANOAXIS, LLCInventors: Krishnan Chakravarthy, Siddhartha Kamisetti, Himanshu Subhash Amin
-
Patent number: 8426154Abstract: Methods and immunoassays for diagnosing a bite or sting of a venomous organism in a patient having symptoms consistent with such a bite or sting are provided. A sample of venom is collected from the area of the suspected bite or sting using a swab and then contacted with an antibody that specifically binds to an antigenic site on venom present in the sample. Binding is then detected. The invention is illustrated by examples showing diagnosis of brown recluse spider bite, distinguishing it from other diagnoses with which it is often confused. This extremely sensitive test can detect venom antigens down to about 20 picograms even after the sample has been shipped and stored for periods of up to three weeks during the summer.Type: GrantFiled: April 8, 2010Date of Patent: April 23, 2013Assignees: SpiderTech, a Division of Stoecker & Associates, a Subsidiary of The Dermatology Center, LLC., The Regents of the University of Michigan, Office of Technology Transfer, The Curators of the University of Missouri, University Hall, The United States of America as Represented by the Secretary of the Air Force, Directorate of Intellectual Property LawInventors: William V. Stoecker, Hernan F. Gomez, Jonathan A. Green, David L. McGlasson
-
Publication number: 20130095495Abstract: The present invention is related to a method for detection of a biological target in an affinity assay, the method comprising the steps of providing a biological sample volume containing the biological target, adding a first capturing moiety to the biological sample volume comprising the biological target, wherein the first capturing moiety is adhered to a particle, concentration of the captured biological target into an elution volume that is smaller than the biological sample volume in step a), cleavage of the first capturing moiety or the biological target from the particle and direct or indirect detection and/or quantification of the biological target in a sandwich or competitive affinity assay format, wherein the biological target is associated with at least one capturing moiety, preferably at least two capturing moieties.Type: ApplicationFiled: June 14, 2011Publication date: April 18, 2013Applicant: KONINKLIJKE PHILIPS ELECTRONICS N.V.Inventors: Gwenola Sabatte, Menno Willem Jose Prins, Toon Hendrik Evers, Wilhelmina Maria Hardeman, Joukje Garrelina Orsel
-
Publication number: 20130095502Abstract: Disclosed herein are reagents that include a moiety that includes a metal such as titanium and that readily binds to phosphorylated molecules the reagents also include at least one moiety that produces a signal or that binds to a molecule that produces a signal. The reagent may also include a moiety that binds to a larger molecule or to a surface. Some forms of the reagent include a dendrimer that can simultaneously bind to multiple metal moieties that include a metal such as titanium and multiple moieties that can be used to detected bound molecules. These reagents can be used in detection and/or measurement and/or at least partial purification of phosphorylated molecules. These reagents and methods using them are used to analyze proteins, polypeptides, nucleic acids, phospholipids and the like. They are readily adapted for use in gels, blots, plate based high through put assays and for mass spectrometry.Type: ApplicationFiled: April 13, 2011Publication date: April 18, 2013Applicant: PURDUE RESEARCH FOUNDATIONInventors: Weiguo A. Tao, Anton B. Iliuk
-
Publication number: 20130095508Abstract: A pipette component for use in performing an experimental procedure with a fluid sample and a pipette, the pipette component including: a pipette interface configured to engage sealingly and separably with a body of the pipette; a tip interface configured to engage sealingly and separably with a replaceable tip; and an experiment region configured to receive at least part of the fluid sample by operation of the pipette, and configured to perform at least part of the experimental procedure in the experiment region using the at least part of the fluid sample.Type: ApplicationFiled: September 17, 2010Publication date: April 18, 2013Applicant: MINIFAB (AUSTRALIA) PTY LTDInventors: Andrew Paul Campitelli, Erol Craig Harvey, John Edward McCormack, Matthew Daniel Solomon, Edward Francis Wilkinson, Michael William Wilkinson, Grit Diessner
-
Patent number: 8420340Abstract: Antibodies, polypeptides, and polynucleotides are provided for the detection, prevention, amelioration and treatment of diseases caused by Actinobacillus actinomycetemcomitans.Type: GrantFiled: May 20, 2011Date of Patent: April 16, 2013Assignee: University of Florida Research FoundationInventors: Martin Handfield, Jeffrey Daniel Hillman, Ann Progulske-Fox
-
Patent number: 8415113Abstract: A procedure for the identification of a functional disorder of the pancreas by the use of parts of all iso-enzymes of the pancreas elastase and of synthetic amino-acid sequences as antigens for obtaining specific antibodies, as well as their use in immuno-chemical test procedures.Type: GrantFiled: September 3, 1999Date of Patent: April 9, 2013Assignee: R-Biopharm AGInventors: Hans-Werner Heinrich, Rainer Kleinert, Udo Meyer, Heinz-Jürgen Wagner
-
Publication number: 20130084586Abstract: Methods for the detection, identification and quantification of gram negative bacteria and gram negative bacterial antigens are rapid, efficient and highly specific. Compositions for the detection and identification of highly variable serogroups are provided.Type: ApplicationFiled: September 28, 2012Publication date: April 4, 2013Applicant: The Penn State Research FoundationInventor: The Penn State Research Foundation
-
Publication number: 20130084587Abstract: Cytokeratins are intermediate filaments in the epithelial cells. Human cancers are malignant counterparts of normal epithelia. Human cancer cells express various kinds of cytokeratins dependent upon the specific cancer cell type. Pathologists have been using cytokeratin immunostaining for classification of tumor origins and cancer types. We claim that the protein levels of cytokeratin 7 (CK7) in the blood and/or body fluids are proportional to the tumor burden, and these protein levels of CK7 can be used as biomarkers for cancer screening, diagnosis and treatment monitoring.Type: ApplicationFiled: October 1, 2011Publication date: April 4, 2013Inventors: Peilin Zhang, Sylvia Tina Zhang, Xianglin Shi
-
Patent number: 8409877Abstract: An embodiment of the invention relates to a device for detecting an analyte in a sample. The device comprises a fluidic network and an integrated circuitry component. The fluidic network comprises a sample zone, a cleaning zone and a detection zone. The fluidic network contains a magnetic particle and/or a signal particle. A sample containing an analyte is introduced, and the analyte interacts with the magnetic particle and/or the signal particle through affinity agents. A microcoil array or a mechanically movable permanent magnet is functionally coupled to the fluidic network, which are activatable to generate a magnetic field within a portion of the fluidic network, and move the magnetic particle from the sample zone to the detection zone. A detection element is present which detects optical or electrical signals from the signal particle, thus indicating the presence of the analyte.Type: GrantFiled: December 29, 2006Date of Patent: April 2, 2013Assignee: Intel CorporationInventors: David J. Liu, Kai Wu, Xing Su
-
Publication number: 20130078656Abstract: The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interaction with the immune system.Type: ApplicationFiled: September 10, 2012Publication date: March 28, 2013Applicants: SANOFI PASTEUR VAXDESIGN CORPORATION, THE WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH, MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE SCRIPPS RESEARCH INSTITUTEInventors: William L. WARREN, Heather FAHLENKAMP, Russell HIGBEE, Anatoly KACHURIN, Conan LI, Mike NGUYEN, Robert PARKHILL, Guzman SANCHEZ-SCHMITZ, Darrell J. IRVINE, Gwendalyn J. RANDOLPH, Nir HACOHEN, Bruce TORBETT
-
Publication number: 20130079296Abstract: The present invention relates to a reliable method of prediction of lower respiratory tract infection or inflammation in humans, wherein the level of pancreatic stone protein/regenerating protein (PSP/reg) is determined in serum, and a high level is indicative of the development and the severity of the disease, allowing the classification of patients according to risk.Type: ApplicationFiled: May 31, 2011Publication date: March 28, 2013Applicants: SEPSTONE DIAGNOSTICS SARL, UNIVERSITY HOSPITAL OF BASELInventors: Daiana Stolz, Frederic Lajaunias
-
Publication number: 20130078657Abstract: The present invention relates to a method for generation of a test-antigen specific cell-mediated immune response by incubating at hyperthermic conditions and, more particularly, a method for generation of a test-antigen specific cell-mediated immune response by incubating at hyperthermic conditions and optionally adding IL-7 and/or blocking IL-10. Even more particularly, the present invention provides a method for generating a cell-mediated response to an antigen using whole blood or other suitable bio-logical samples. The method is useful in for immune diagnosis of many infectious diseases, as a marker of immunocompetence, and for detection of T-cell responses to non-self antigens (i.e. infections and vaccines).Type: ApplicationFiled: May 4, 2011Publication date: March 28, 2013Applicant: Hvidovre HospitalInventors: Morten Ruhwald, Jesper Eugen-Olsen, Pernille Ravn, Martine Grosos Aabye
-
Publication number: 20130078655Abstract: The invention provides a method of predicting subjects at risk of loss of kidney function and/or identifying subjects at greater risk of loss of kidney function, and/or identifying subjects at risk of kidney failure/end stage kidney disease, the method comprising detecting an amount of free light chains (FLC) in a sample from the subject, wherein a higher amount of FLC is associated with increased risk of loss of kidney function and/or increased risk of renal failure/end stage kidney disease.Type: ApplicationFiled: March 3, 2011Publication date: March 28, 2013Applicant: THE BINDING SITE GROUP LIMITEDInventor: Arthur R. Bradwell
-
Publication number: 20130071865Abstract: The present invention relates to a diagnostic method for the detection of small quantities of amniotic fluid in the vagina. More specifically, the invention relates to the detection of PAMG-1 in the vagina using anti-PAMG-1 antibodies.Type: ApplicationFiled: November 13, 2012Publication date: March 21, 2013Applicant: N-DIA, INC.Inventor: N-Dia, Inc.